Recerca

Àrea 1

Immunoreceptors del sistema innat i adaptatiu

Articles de l'any 2010
Original

Originals publicats: 11

Factor d'impacte: mitjana: 5.04, total: 55.45

  • ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1

    Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, Engel P, Postigo A
    ONCOGENE. 2010; 29: 3490-3500. IF: 7.135

  • Cutting Edge: The Adapters EAT-2A and -2B Are Positive Regulators of CD244- and CD84-Dependent NK Cell Functions in the C57BL/6 Mouse

    Wang NH, Calpe S, Westcott J, Castro W, Ma CY, Engel P, Schatzle JD, Terhorst C
    J IMMUNOL. 2010; 185: 5683-5687. IF: 5.646

  • Serotype-specific pneumococcal disease may be influenced by mannose-binding lectin deficiency

    Valles X, Roca A, Lozano F, Morais L, Suarez B, Casals F, Mandomando I, Sigauque B, Nhalungo D, Esquinas C, Quinto L, Alonso PL, Torres A
    EUR RESPIR J. 2010; 36: 856-863. IF: 5.527

  • Enhancerless Cytomegalovirus Is Capable of Establishing a Low-Level Maintenance Infection in Severely Immunodeficient Host Tissues but Fails in Exponential Growth

    Podlech J, Pintea R, Kropp KA, Fink A, Lemmermann NAW, Erlach KC, Isern E, Angulo A, Ghazal P, Reddehase MJ
    J VIROL. 2010; 84: 6254-6261. IF: 5.15

  • Mouse CD84 is a pan-leukocyte cell-surface molecule that modulates LPS-induced cytokine secretion by macrophages

    Sintes J, Romero X, DeSalort J, Terhorst C, Engel P
    J LEUKOCYTE BIOL. 2010; 88: 687-697. IF: 4.403

Més articles
Tesis
  • Influencia de los poliformismos de los genes de la inmunidad innata en el desarrollo y evolución de las infecciones tras un trasplante de órgano sólido

    Doctorand: Carlos Cervera Alvarez,
    Director/s: Lozano F, Moreno A

Patents
  • Pharmaceutical composition useful for preventing and/or treating fungal infection, fungal sepsis, and/or any inflammatory disorder triggered by fungal components, comprises soluble CD5 ectodomain and at least a pharmaceutical excipient

    HOSPITAL CLINIC I PROVINCIAL BARCELONA; FUNDACIO CLINIC PER A LA RECER

  • Use of CD6 product for manufacturing a drug, for treating and/or preventing a bacterial infection or an inflammatory process related to an infectious disease, e.g. microbial infection or a related inflammatory process, e.g. sepsis

    UNIV BARCELONA